{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:23:25Z","timestamp":1793877805969,"version":"4.7.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007605"],"award-info":[{"award-number":["T32HL007605"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL146942"],"award-info":[{"award-number":["K23HL146942"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mortality prediction in interstitial lung disease (ILD) poses a significant challenge to clinicians due to heterogeneity across disease subtypes. Currently, forced vital capacity (FVC) and Gender, Age, and Physiology (GAP) score are the two most utilized metrics in prognostication. Recently, a machine learning classifier system, Fibresolve, designed to identify a variety of computed tomography (CT) patterns associated with idiopathic pulmonary fibrosis (IPF), was demonstrated to have a significant association with mortality across multiple subtypes of ILD. The purpose of this follow-up study was to retrospectively validate these findings in a large, external cohort of patients with ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multi-center validation study, Fibresolve was applied to chest CT scans of patients with confirmed ILD that had available follow-up data. Fibresolve scores categorized by tertile were analyzed using Cox regression analysis adjusted for tobacco use and modified GAP (mGAP) score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 643 patients included, 446 (69.3%) died over a median follow-up time of 144 [1-821] weeks. The median [range] mGAP score was 5 [3\u20137]. In multivariable analysis, Fibresolve score categorized by tertile was significantly associated with mortality (Tertile 2\u00a0HR 1.47, 95% CI 0.82\u20132.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.11; Tertile 3\u00a0HR 3.12, 95% CI 1.98\u20134.90,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Subgroup analyses revealed significant associations amongst those with non-IPF ILDs (Tertile 2\u00a0HR 1.95, 95% CI 1.28\u20132.97, Tertile 3\u00a0HR 4.66, 95% CI 2.94\u20137.38) and severe disease, defined by a FVC\u2009\n                      <jats:underline>\u2264<\/jats:underline>\n                      \u200975% (Tertile 2\u00a0HR 2.29, 95% CI 1.43\u20133.67, Tertile 3\u00a0HR 4.80, 95% CI 2.93\u20137.86).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fibresolve is independently associated with mortality in ILD, particularly amongst patients with non-IPF ILDs and in those with severe disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-024-03021-w","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T05:02:30Z","timestamp":1716440550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Machine learning classifier is associated with mortality in interstitial lung disease: a retrospective validation study leveraging registry data"],"prefix":"10.1186","volume":"24","author":[{"given":"Kavitha C.","family":"Selvan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Reicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Muelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angad","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodeji","family":"Adegunsoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"3021_CR1","first-page":"PA3753","volume":"58","author":"MM Molina","year":"2023","unstructured":"Molina MM, Hart E, Lesher B, Ribera A, Langley J, Patel H. Association between FVC and mortality in idiopathic pulmonary fibrosis: a systematic literature review. Eur Respir J. 2023;58:PA3753.","journal-title":"Eur Respir J"},{"key":"3021_CR2","doi-asserted-by":"publisher","first-page":"754851","DOI":"10.3389\/fphar.2021.754851","volume":"12","author":"X Chen","year":"2021","unstructured":"Chen X, Guo J, Yu D, Jie B, Zhou Y. Predictors of mortality in progressive fibrosing interstitial lung disease. Front Pharmacol. 2021;12:754851.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3021_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/thoraxjnl-2017-210035","volume":"73","author":"A Gimenez","year":"2018","unstructured":"Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic hypersensitivity pneumonitis. Thorax. 2018;73(4):391\u20132.","journal-title":"Thorax"},{"issue":"10","key":"3021_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Rya JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684\u201391.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3021_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Reyerson","year":"2014","unstructured":"Reyerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723\u20138.","journal-title":"Chest"},{"issue":"5","key":"3021_CR6","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1513\/AnnalsATS.201807-443OC","volume":"16","author":"A Adegunsoye","year":"2019","unstructured":"Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Annals Am Thorac Soc. 2019;16(5):580\u20138.","journal-title":"Annals Am Thorac Soc"},{"issue":"4","key":"3021_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/resp.14231","volume":"27","author":"KK Brown","year":"2022","unstructured":"Brown KK, Inoue Y, Flaherty KR, Martinez FJ, Cottin V, Bonella F, et al. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology. 2022;27(4):294\u2013300.","journal-title":"Respirology"},{"issue":"5","key":"3021_CR8","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1183\/13993003.00129-2016","volume":"48","author":"AJ Podolanczuk","year":"2016","unstructured":"Podolanczuk AJ, Oelsner EC, Barr RG, Hoffman EA, Armstrong HF, Austin JHM, et al. High attenuation areas on chest CT in community-dwelling adults: the MESA study. Eur Respir J. 2016;48(5):1442\u201352.","journal-title":"Eur Respir J"},{"issue":"11","key":"3021_CR9","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1164\/rccm.201703-0555OC","volume":"196","author":"AJ Podolanczuk","year":"2017","unstructured":"Podolanczuk AJ, Oelsner EC, Barr RG, Bernstein EJ, Hoffman EA, Easthausen IJ, et al. High attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults. Am J Respir Crit Care Med. 2017;196(11):1434\u201342.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3021_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1148\/radiol.2017161177","volume":"285","author":"SM Humphries","year":"2017","unstructured":"Humphries SM, Yagihashi K, Huckleberry J, Rho B-H, Schroeder JD, Strand M, et al. Idiopathic pulmonary fibrosis: data-driven textural analysis of extent of fibrosis at baseline at 15-month follow-up. Radiology. 2017;285(1):270\u20138.","journal-title":"Radiology"},{"key":"3021_CR11","doi-asserted-by":"publisher","unstructured":"Ahmad Y, Mooney JJ, Allen I, Seaman J, Kalra A, Muelly M et al. A machine learning system to predict diagnosis of idiopathic pulmonary fibrosis non-invasively in challenging cases. Available at SSRN: https:\/\/ssrn.com\/abstract=4353892 or https:\/\/doi.org\/10.2139\/ssrn.4353892","DOI":"10.2139\/ssrn.4353892"},{"key":"3021_CR12","doi-asserted-by":"publisher","first-page":"107428","DOI":"10.1016\/j.rmed.2023.107428","volume":"219","author":"M Maddali","year":"2023","unstructured":"Maddali M, Kalra A, Muelly M, Reicher J. Development and validation of a CT-based deep learning algorithm to augment non-invasive diagnosis of idiopathic pulmonary fibrosis. Respir Med. 2023;219:107428.","journal-title":"Respir Med"},{"key":"3021_CR13","first-page":"PA3824","volume":"46","author":"S Low","year":"2015","unstructured":"Low S. Using the ILD-GAP model to predict mortality in chronic interstitial lung disease. Eur Respir J. 2015;46:PA3824.","journal-title":"Eur Respir J"},{"key":"3021_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.rmed.2019.02.015","volume":"150","author":"RM Brusca","year":"2019","unstructured":"Brusca RM, Pinal-Fernandez I, Psoter K, Paik JJ, Albayda J, Mecoli C, et al. The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. Resp Med. 2019;150:63\u20135.","journal-title":"Resp Med"},{"key":"3021_CR15","doi-asserted-by":"crossref","unstructured":"Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Nair A, Karwoski R et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J. 2017;49(1).","DOI":"10.1183\/13993003.01011-2016"},{"issue":"6","key":"3021_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1164\/rccm.201711-2174OC","volume":"198","author":"J Jacob","year":"2018","unstructured":"Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, et al. Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. Am J Respir Crit Care Med. 2018;198(6):767\u201376.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3021_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1183\/09031936.00071812","volume":"43","author":"F Maldonado","year":"2014","unstructured":"Maldonado F, Moua T, Rajagopalan S, Karwoski RA, Raghunath S, Decker PA, et al. Automated quantification of radiologic patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(1):204\u201312.","journal-title":"Eur Respir J"},{"issue":"11","key":"3021_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/S2213-2600(20)30003-5","volume":"8","author":"SL Walsh","year":"2020","unstructured":"Walsh SL, Humphries SM, Wells AU, Brown KK. Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. Lancet Respir Med. 2020;8(11):1144\u201353.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"3021_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S2213-2600(18)30286-8","volume":"6","author":"SLF Walsh","year":"2018","unstructured":"Walsh SLF, Calandriello L, Silva M, Sverzellati N. Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study. Lancet Respir Med. 2018;6(11):837\u201345.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"3021_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1164\/rccm.202112-2684OC","volume":"206","author":"SLF Walsh","year":"2022","unstructured":"Walsh SLF, Mackintosh JA, Calandriello L, Silva M, Sverzellati N, Larici AR, et al. Deep learning-based outcome prediction in progressive fibrotic lung disease using high-resolution computed tomography. Am J Respir Crit Care Med. 2022;206(7):883\u201391.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3021_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12931-020-01371-7","volume":"21","author":"N Taha","year":"2020","unstructured":"Taha N, D\u2019Amato D, Hosein K, Ranalli T, Sergiacomi G, Zompatori M, Mura M. Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters? Respir Res. 2020;21(1):119. https:\/\/doi.org\/10.1186\/s12931-020-01371-7. PMID: 32429952; PMCID: PMC7238541.","journal-title":"Respir Res"},{"issue":"8","key":"3021_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1164\/rccm.200402-147OC","volume":"170","author":"KR Flaherty","year":"2004","unstructured":"Flaherty KR, King TE Jr, Raghu G, Lynch JP, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904\u201310.","journal-title":"Am J Respir Crit Care Med"},{"key":"3021_CR23","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, de Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Eng J Med. 2014;370:2071\u201382.","journal-title":"N Eng J Med"},{"key":"3021_CR24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung disease. N Eng J Med. 2019;381:1718\u201327.","journal-title":"N Eng J Med"},{"key":"3021_CR25","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Eng J Med. 2014;370:2083\u201392.","journal-title":"N Eng J Med"},{"key":"3021_CR26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41379-022-01025-7","volume":"35","author":"W Uegami","year":"2022","unstructured":"Uegami W, Bychkov A, Ozasa M, Uehara K, Kataoka K, Johkoh T, et al. Mixture of human expertise and deep learning \u2013 developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease. Mod Path. 2022;35:1083\u201391.","journal-title":"Mod Path"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03021-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03021-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03021-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T05:04:11Z","timestamp":1716440651000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03021-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3021"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03021-w","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We consulted extensively with Argus Institutional Review Board (IRB) who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from Argus IRB. The data protocols are in accordance with the ethical standards of our institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all participants included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.S. has no competing interests. J.R., M.M., and A.K. have a financial interest in IMVARIA Inc. A.A. has relationships with Genentech Inc., Inongen Inc., Medscape LLC, PatientMpower, Abbvie, and Boehringer Ingelheim Corp USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}